¼¼°èÀÇ °ñ°üÀý¿° ÁÖ»çÁ¦ ½ÃÀå
Osteoarthritis Injectables
»óǰÄÚµå : 1782982
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 379 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

°ñ°üÀý¿° ÁÖ»çÁ¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 100¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 75¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â °ñ°üÀý¿° ÁÖ»çÁ¦ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 100¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ È÷¾Ë·ç·Ð»ê ÁÖ»ç´Â CAGR 4.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 25¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÁÖ»ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 20¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °ñ°üÀý¿° ÁÖ»çÁ¦ ½ÃÀåÀº 2024³â¿¡ 20¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 7.8%¸¦ ´õµë¾î, 2030³â±îÁö 20¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.5%¿Í 4.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ °ñ°üÀý¿° ÁÖ»çÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

°ñ°üÀý¿° ÁÖ»çÁ¦´Â ÅëÁõ °ü¸®¿Í °üÀý Ä¡·á¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

°ñ°üÀý¿° ÁÖ»çÁ¦ ½ÃÀåÀº °üÀýÀÇ ÅëÁõ°ú ¿°ÁõÀ» °ü¸®Çϱâ À§ÇÑ ºñ¼ö¼úÀû Ä¡·á ¿É¼ÇÀÌ Á¡Á¡ ´õ ¼±È£µÇ¸é¼­ Å« °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. °ñ°üÀý¿°(OA)ÀÌ Àü ¼¼°è ¼ö¹é¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ´Â °¡¿îµ¥, ȯÀÚ¿Í ÀÇ·áÁøÀº Àΰø°üÀý ġȯ¼úÀ» ´ÊÃ߰ųª ÇÇÇÒ ¼ö ÀÖ´Â ÃÖ¼Òħ½ÀÀû ÇØ°áÃ¥À» ã°í ÀÖ½À´Ï´Ù. ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å, È÷¾Ë·ç·Ð»ê, Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP), Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¿Í °°Àº ÁÖ»ç ¿ä¹ýÀº ÅëÁõ ¿ÏÈ­, °üÀý °¡µ¿¹üÀ§ °³¼±, ¿¬°ñ °Ç°­ ÁõÁø µîÀÇ È¿°ú·Î ÀÎÇØ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ºñ¸¸À² Áõ°¡´Â OAÀÇ µÎ °¡Áö ÁÖ¿ä À§Çè ¿äÀÎÀ¸·Î, °æ±¸¿ë ÁøÅëÁ¦¿¡ ¼ö¹ÝµÇ´Â ºÎÀÛ¿ë ¾øÀÌ Àå±âÀûÀÎ ¿ÏÈ­¸¦ Á¦°øÇÏ´Â È¿°úÀûÀÎ ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

°ñ°üÀý¿° Ä¡·á¿¡¼­ »õ·Î¿î »ý¹°ÇÐÀû Ä¡·á¿Í Àç»ý Ä¡·á´Â ¾î¶² ¿ªÇÒÀ» ÇÒ ¼ö ÀÖÀ»±î?

°ñ°üÀý¿° Ä¡·á ȯ°æÀº »ý¹°ÇÐÀû ÁÖ»çÁ¦ ¹× Àç»ýÀÇ·á Á¢±Ù¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¯È­Çϰí ÀÖ½À´Ï´Ù. ȯÀÚ ÀÚ½ÅÀÇ Ç÷¾× À¯·¡ ¼ºÀåÀÎÀÚ¸¦ ÀÌ¿ëÇÏ´Â PRP ¿ä¹ýÀº ±âÁ¸ÀÇ ½ºÅ×·ÎÀ̵å Áֻ縦 ´ëüÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ Ä¡·á¹ýÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ýµµ ºÎ»óÇϰí ÀÖÀ¸¸ç, ´Ü¼øÇÑ ´ëÁõ¿ä¹ýÀÌ ¾Æ´Ñ ¿¬°ñ Àç»ý°ú Àå±âÀûÀÎ Áúȯ °³¼±ÀÇ °¡´É¼ºÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡±³¿ä¹ý ¹× º´¿ë¿ä¹ýÀ» Æ÷ÇÔÇÑ È÷¾Ë·ç·Ð»ê Á¦Á¦ÀÇ ¹ßÀüÀ¸·Î °üÀý³» ġȯ¼úÀÇ ³»±¸¼º°ú À¯È¿¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¿°Áõ °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â À¯ÀüÀÚ Ä¡·á¿Í ´ÜŬ·ÐÇ×ü ¿¬±¸µµ ÁøÇà ÁßÀ̸ç, OA °ü¸®¿¡ Çõ¸íÀ» °¡Á®¿Ã Â÷¼¼´ë ÁÖ»ç Ä¡·áÁ¦°¡ ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

°ñ°üÀý¿° ÁÖ»çÁ¦ º¸±ÞÀ» °¡·Î¸·´Â °úÁ¦´Â ¹«¾ùÀϱî?

ÀÌ·¯ÇÑ È¿°ú¿¡µµ ºÒ±¸Çϰí, °ñ°üÀý¿° ÁÖ»çÁ¦ÀÇ º¸±Þ¿¡´Â ¸î °¡Áö À庮ÀÌ Á¸ÀçÇÕ´Ï´Ù. ³ôÀº Ä¡·áºñ, ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦³ª Áٱ⼼Æ÷¸¦ ÀÌ¿ëÇÑ Ä¡·á´Â ¸¹Àº ȯÀÚµéÀÇ Ä¡·á Á¢±Ù¼ºÀ» Á¦ÇÑÇÏ´Â Å« ¹®Á¦Á¡À¸·Î ³²¾ÆÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó °á°úÀÇ ÆíÂ÷¿Í »õ·Î¿î Àç»ýÄ¡·á¿¡ ´ëÇÑ Ç¥ÁØÈ­µÈ ÇÁ·ÎÅäÄÝÀÇ ºÎÀç´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÀÇ»çÀÇ Ã¤¿ë¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å¿Í °°Àº ÀϺΠÁÖ»ç ¿ä¹ýÀº Àå±â°£ »ç¿ëÀ¸·Î ÀÎÇÑ ¿¬°ñÀÇ ¾ÇÈ­¸¦ Æ÷ÇÔÇÑ ÀáÀçÀûÀÎ ºÎÀÛ¿ë°ú °ü·ÃÀÌ ÀÖ¾î ½ÅÁßÇÏ°Ô Ã³¹æµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸¿Í ÀÓ»ó½ÃÇèÀ» ÅëÇØ ÀÌ·¯ÇÑ ÇѰ踦 ±Øº¹Çϰí, Á¦ÇüÀ» °³¼±Çϰí, Åõ¿© ¿ä¹ýÀ» ÃÖÀûÈ­ÇÏ¿© Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» ³ôÀ̱â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

°ñ°üÀý¿° ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀϱî?

°ñ°üÀý¿° ÁÖ»çÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº °ñ°üÀý¿° À¯º´·ü Áõ°¡, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, »ý¹°ÇÐÀû Ä¡·á ¹× Àç»ý Ä¡·áÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¿Ü·¡ ¹× ³»°úÀû ½Ã¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ¿Ü°úÀû °³ÀÔº¸´Ù ÁÖ»ç ¿ä¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¢±¹ÀÇ È÷¾Ë·ç·Ð»ê ¹× PRP Áֻ翡 ´ëÇÑ ±Þ¿© Á¤Ã¥ÀÇ È®´ë°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ½Å±Ô °ñ°üÀý¿° Ä¡·áÁ¦ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ÇÔ²² ½ÃÀå È®´ë¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë ¾à¹°ÀÇ ÃâÇö

ºÎ¹®

ÁÖ»çÁ¦(È÷¾Ë·ç·Ð»ê ÁÖ»çÁ¦, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÁÖ»çÁ¦, Ç÷¼ÒÆÇ dzºÎ Ç÷Àå ÁÖ»çÁ¦, ÅÂ¹Ý Á¶Á÷ ¸ÅÆ®¸¯½º ÁÖ»çÁ¦, ¾Æ¼¼Æ¿ »ì¸®½Ç»ê ÁÖ»çÁ¦, ±âŸ ÁÖ»çÁ¦), ÇØºÎÇÐ(½½°üÀý °ñ°üÀý¿°, °í°üÀý °ñ°üÀý¿°, ¼Õ °ñ°üÀý¿°, ±âŸ ÇØºÎÇÐ), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ¾à±¹ ÃÖÁ¾»ç¿ëÀÚ, ¼Ò¸Å ¾à±¹ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Osteoarthritis Injectables Market to Reach US$10.0 Billion by 2030

The global market for Osteoarthritis Injectables estimated at US$7.5 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Hyaluronic Acid Injections, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Corticosteroid Injections segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 7.8% CAGR

The Osteoarthritis Injectables market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Osteoarthritis Injectables Market - Key Trends & Drivers Summarized

How Are Osteoarthritis Injectables Transforming Pain Management and Joint Care?

The osteoarthritis injectables market has gained significant traction as non-surgical treatment options for managing joint pain and inflammation become increasingly preferred. With osteoarthritis (OA) affecting millions worldwide, patients and healthcare providers are seeking minimally invasive solutions to delay or avoid joint replacement surgery. Injectable therapies, including corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell-based treatments, are being widely adopted due to their ability to provide targeted pain relief, improve joint mobility, and enhance cartilage health. The aging global population and rising obesity rates-two major risk factors for OA-are further fueling the demand for effective injectables that offer prolonged relief without the side effects associated with oral pain medications.

What Role Do Emerging Biologic and Regenerative Therapies Play in Osteoarthritis Treatment?

The landscape of osteoarthritis treatment is shifting with the increasing adoption of biologic injectables and regenerative medicine approaches. PRP therapy, which utilizes the patient's own blood-derived growth factors, has gained popularity as a promising alternative to traditional steroid injections. Stem cell-based therapies are also emerging, offering the potential for cartilage regeneration and long-term disease modification rather than just symptomatic relief. Additionally, advancements in hyaluronic acid formulations, including cross-linked and combination therapies, are improving the durability and efficacy of viscosupplementation. Research into gene therapy and monoclonal antibodies targeting inflammatory pathways is also underway, promising next-generation injectable treatments that could revolutionize OA management.

What Are the Key Challenges Limiting the Adoption of Osteoarthritis Injectables?

Despite their effectiveness, several barriers exist in the widespread adoption of osteoarthritis injectables. High treatment costs, particularly for biologic and stem cell-based therapies, remain a significant concern, limiting accessibility for many patients. Additionally, variability in clinical outcomes and the lack of standardized protocols for emerging regenerative treatments pose challenges for regulatory approval and physician adoption. Some injectable therapies, such as corticosteroids, have been associated with potential side effects, including cartilage degradation with prolonged use, leading to cautious prescribing practices. However, ongoing research and clinical trials are working to address these limitations, refining formulations and optimizing dosing regimens to enhance treatment efficacy and safety.

What’s Fueling the Growth of the Osteoarthritis Injectables Market?

The growth in the osteoarthritis injectables market is driven by several factors, including the increasing prevalence of osteoarthritis, rising demand for minimally invasive treatments, and advancements in biologic and regenerative therapies. The growing preference for outpatient and in-office procedures has boosted the adoption of injectable therapies over surgical interventions. Additionally, the expansion of reimbursement policies covering hyaluronic acid and PRP injections in various countries is supporting market growth. The rising geriatric population, along with increasing investments in R&D for novel osteoarthritis therapeutics, is further accelerating market expansion. The emergence of next-generation

SCOPE OF STUDY:

The report analyzes the Osteoarthritis Injectables market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Injection (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet-Rich Plasma Injections, Placental Tissue Matrix Injections, Acetylsalicylic Acid Injections, Other Injections); Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, Other Anatomies); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â